product name Clinafloxacin
Description: Clinafloxacin (also known as CI-960, PD127391, AM-1091) is a fluoroquinolone antibiotic that inhibits both DNA gyrase and topoisomerase IV dually in Streptococcus pneumonia. It is a broad-spectrum antibiotic of the quinolone carboxylic acid class currently in development for intravenous and oral therapy of serious infections. Clinafloxacin is a novel fluoroquinolone antibiotic with potent broad-spectrum in vitro activity against gram-positive, gram-negative, and anaerobic pathogens.
References: J Clin Pharmacol. 1999 Nov;39(11):1143-50; Antimicrob Agents Chemother. 1998 Nov;42(11):2810-6.
365.79
Formula
C17H17ClFN3O3
CAS No.
105956-97-6
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: <1 mg/mL
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
CI-960, PD127391, AM-1091
other peoduct :
| In Vitro |
In vitro activity: Clinafloxacin is a broad-spectrum antibiotic of the quinolone carboxylic acid category currently in development for intravenous and oral therapy of serious infections. Clinafloxacin is a novel fluoroquinolone with potent broad-spectrum in vitro activity against gram-positive, gram-negative, and anaerobic pathogens. Clinafloxacin is highly active against S. pneumoniae 7785 (MIC, 0.125 μg/mL), and neither gyrA nor parC quinolone resistance mutations alone have much effect on this activity. Clinafloxacin is identified as the most active fluoroquinolone against S. pneumoniae when compared with ofloxacin, levofloxacin, sparfloxacin, grepafloxacin, and trovafloxacin and is currently being evaluated as an antipneumococcal agent. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | J Clin Pharmacol. 1999 Nov;39(11):1143-50; Antimicrob Agents Chemother. 1998 Nov;42(11):2810-6. |
